Published
2023-10-12
Issue
Section
Original Research Article
License
The Author(s) warrant that permission to publish the article has not been previously assigned elsewhere.
Author(s) shall retain the copyright of their work and grant the Journal/Publisher right for the first publication with the work simultaneously licensed under:
OA - Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license allows for the copying, distribution and transmission of the work, provided the correct attribution of the original creator is stated. Adaptation and remixing are also permitted.
This license intends to facilitate free access to, as well as the unrestricted reuse of, original works of all types for non-commercial purposes.
How to Cite
Omicron variants of SARS CoV-2 indicate a new antiviral strategy: interfering with spike glycoprotein trimerization
Neri Niccolai
Department of Biotechnology, Chemistry and Pharmacy, University of Siena; Le Ricerche del BarLume Free Association, Ville di Corsano, Monteroni d’Arbia
Alfonso Trezza
Department of Biotechnology, Chemistry and Pharmacy, University of Siena
Federico Marchini
Department of Biotechnology, Chemistry and Pharmacy, University of Siena
Pietro Bongini
Department of Information Engineering and Mathematics, University of Siena
Monica Bianchini
Department of Information Engineering and Mathematics, University of Siena
Annalisa Santucci
Department of Biotechnology, Chemistry and Pharmacy, University of Siena; Industry 4.0 Competence Center ARTES 4.0 Viale Rinaldo Piaggio
Ottavia Spiga
Department of Biotechnology, Chemistry and Pharmacy, University of Siena; Industry 4.0 Competence Center ARTES 4.0 Viale Rinaldo Piaggio
Anna Visibelli
Department of Biotechnology, Chemistry and Pharmacy, University of Siena
Keywords: SARS-CoV-2, Omicron variants, sequence variability, spike glycoprotein, structure disassembly, interfering ligands
References
1. Miljanovic D, Cirkovic A, Lazarevic I, et al. Clinical efficacy of anti-SARS-CoV-2 monoclonal antibodies in preventing hospitalisation and mortality among patients infected with Omicron variants: A systematic review and meta-analysis. Reviews in Medical Virology 2023; 33(4): e2439. doi: 10.1002/rmv.24392. Zhou Y, Wang H, Yang L, Wang Q. Progress on COVID-19 chemotherapeutics discovery and novel technology. Molecules 2022; 27(23): 8257. doi: 10.3390/molecules27238257
3. Zhan W, Tian X, Zhang X, et al. Structural study of SARS-CoV-2 antibodies identifies a broad-spectrum antibody that neutralizes the omicron variant by disassembling the spike trimer. Journal of Virology 2022; 96(16): e0048022. doi: 10.1128/jvi.00480-22
4. Bongini P, Trezza A, Bianchini M, et al. A possible strategy to fight COVID-19: Interfering with spike glycoprotein trimerization. Biochemical and Biophysical Research Communications 2020; 528(1): 35–38. doi: 10.1016/j.bbrc.2020.04.007
5. Delmas B, Laude H. Assembly of coronavirus spike protein into trimers and its role in epitope expression. Journal of Virology 1990; 64(11): 5367–5375. doi: 10.1128/JVI.64.11.5367-5375
6. Sievers F, Wilm A, Dineen D, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Molecular Systems Biology 2011; 7: 539. doi: 10.1038/msb.2011.75
7. Bakan A, Dutta A, Mao W, et al. Evol and ProDy for bridging protein sequence evolution and structural dynamics. Bioinformatics 2014; 30(18): 2681–2683. doi: 10.1093/bioinformatics/btu336
8. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367(6483): 1260–1263. doi: 10.1126/science.abb2507
9. Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. Journal of Molecular Biology 2007; 372(3): 774–797. doi: 10.1016/j.jmb.2007.05.022
10. Koebel MR, Schmadeke G, Posner RG, Sirimulla S. AutoDock VinaXB: Implementation of XBSF, new empirical halogen bond scoring function, into AutoDock Vina. Journal of Cheminformatics 2016; 8(1): 27. doi: 10.1186/s13321-016-0139-1
11. Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Research 2018; 46(D1): D1074–D1082. doi: 10.1093/nar/gkx1037
12. Magazine N, Zhang T, Wu Y, et al. Mutations and evolution of the SARS-CoV-2 spike protein. Viruses 2022; 14(3): 640. doi: 10.3390/v14030640
13. Mistry P, Barmania F, Mellet J, et al. SARS-CoV-2 variants, vaccines, and host immunity. Frontiers in Immunology 2022; 12: 809244. doi: 10.3389/fimmu.2021.809244
14. Alkhatib M, Salpini R, Carioti L, et al. Update on SARS-CoV-2 omicron variant of concern and its peculiar mutational profile. Microbiology Spectrum 2022; 10(2): e0273221. doi: 10.1128/spectrum.02732-21
15. Gurung AB, Ali MA, Lee J, et al. The potential of Paritaprevir and Emetine as inhibitors of SARS-CoV-2 RdRp. Saudi Journal of Biological Sciences 2021; 28(2): 1426–1432. doi: 10.1016/j.sjbs.2020.11.078
16. Kemp SA, Collier DA, Datir RP, et al. Author correction: SARS-CoV-2 evolution during treatment of chronic infection. Nature 2022; 608(7922): E23. doi: 10.1038/s41586-022-05104-2
17. Araf Y, Akter F, Tang YD, et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. Journal of Medical Virology 2022; 94(5): 1825–1832. doi: 10.1002/jmv.27588
18. Farheen S, Araf Y, Tang YD, Zheng C. The Deltacron conundrum: Its origin and potential health risks. Journal of Medical Virology 2022; 94(11): 5096–5102. doi: 10.1002/jmv.27990